HTG Molecular Diagnostics and Sanofi US Collaborate to Identify B-cell Malignancy Biomarkers

Development of Tests That Help Identify Patients Most Likely to Respond to Targeted Therapy Is a Key Step Toward the Personalization of Medicine

(firmenpresse) - TUCSON, AZ -- (Marketwire) -- 03/30/12 -- HTG Molecular Diagnostics has established a collaborative program with Sanofi US to identify biomarkers that may lead to the development of a molecular companion diagnostic test to help identify patients most likely to respond to a novel Sanofi investigational agent. HTG Molecular Diagnostics' qNPA technology measures mRNA and/or miRNA expression in formalin fixed paraffin embedded (FFPE) tumor samples, allowing clinicians to verify the presence of certain biomarkers relevant to patient selection and therapy.

"We are pleased to be a partner with Sanofi in answering the need for personalized cancer treatments. qNPA offers options in diagnostics testing of FFPE tissues not available in other commercial technologies," said TJ Johnson, CEO of HTG Molecular Diagnostics.

HTG Molecular Diagnostics is a privately-held, Tucson-based company providing products for gene expression profiling, miRNA, siRNA and mRNA measurement for clinical research, companion diagnostic and prognostic applications in oncology. The company's qNPA molecular technology platform is well-suited for reliably detecting changes in gene expression levels especially from formalin-fixed, paraffin-embedded (FFPE) tissue. Additional information is available at .



Kimberly Schmitz
Spur Public Relations.
520.247.5778


TJ Johnson
Chief Executive Officer
HTG Molecular Diagnostics
520.547.2827

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: MARKETWIRE
Datum: 30.03.2012 - 11:00 Uhr
Sprache: Deutsch
News-ID 130311
Anzahl Zeichen: 0

contact information:
Town:

TUCSON, AZ

Kategorie:

Biotech

Diese Pressemitteilung wurde bisher 257 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"HTG Molecular Diagnostics and Sanofi US Collaborate to Identify B-cell Malignancy Biomarkers"
steht unter der journalistisch-redaktionellen Verantwortung von

HTG Molecular Diagnostics (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

HTG Announces Completion of IVD Development and Supply Agreement With Illumina ...

TUCSON, AZ -- (Marketwired) -- 10/30/14 -- HTG Molecular Diagnostics, Inc. (HTG), a provider of instruments and reagents for molecular profiling applications, today announced that it entered into an agreement with Illumina, Inc. (NASDAQ: ILMN), unde ...

The PROOF Centre of Excellence Partners With HTG Molecular Diagnostics to Begin ...

TUCSON, AZ -- (Marketwired) -- 09/25/13 -- The Centre of Excellence for the Prevention of Organ Failure (PROOF Centre) and HTG Molecular Diagnostics are collaborating to begin clinical validation of a biomarker blood test that will provide early ind ...

NIH Awards HTG Molecular Additional $1.01M to Continue Development of Targeted S ...

TUCSON, AZ -- (Marketwired) -- 09/04/13 -- The National Human Genome Research Institute of the National Institutes of Health issued a Notice of Award granting a Phase II SBIR award of $1.01 million for to continue the Nuclease Probe Mediated Sequen ...

Alle Meldungen von HTG Molecular Diagnostics